[go: up one dir, main page]

ZA201403006B - Composition for use in treatment of cancer - Google Patents

Composition for use in treatment of cancer

Info

Publication number
ZA201403006B
ZA201403006B ZA2014/03006A ZA201403006A ZA201403006B ZA 201403006 B ZA201403006 B ZA 201403006B ZA 2014/03006 A ZA2014/03006 A ZA 2014/03006A ZA 201403006 A ZA201403006 A ZA 201403006A ZA 201403006 B ZA201403006 B ZA 201403006B
Authority
ZA
South Africa
Prior art keywords
cancer
treatment
composition
Prior art date
Application number
ZA2014/03006A
Inventor
Morole Nthedi Bogoshi
Original Assignee
Indigenous Therapies Holdings (Pty) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indigenous Therapies Holdings (Pty) Ltd filed Critical Indigenous Therapies Holdings (Pty) Ltd
Priority to ZA2014/03006A priority Critical patent/ZA201403006B/en
Publication of ZA201403006B publication Critical patent/ZA201403006B/en

Links

ZA2014/03006A 2014-04-24 2014-04-24 Composition for use in treatment of cancer ZA201403006B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ZA2014/03006A ZA201403006B (en) 2014-04-24 2014-04-24 Composition for use in treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA2014/03006A ZA201403006B (en) 2014-04-24 2014-04-24 Composition for use in treatment of cancer

Publications (1)

Publication Number Publication Date
ZA201403006B true ZA201403006B (en) 2015-10-28

Family

ID=60997038

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/03006A ZA201403006B (en) 2014-04-24 2014-04-24 Composition for use in treatment of cancer

Country Status (1)

Country Link
ZA (1) ZA201403006B (en)

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL248455A0 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
IL276733A (en) Use of eribulin in the treatment of cancer
IL251630A0 (en) Combination therapy for use in cancer therapy
SMT202100115T1 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumours
PT3200815T (en) Methods and compositions for treating cancer
IL251905B (en) Apilimod for use in the treatment of renal cancer
IL248767B (en) Trimethoxyphenyl-benzimidazole compound for use in the treatment of cancer
IL251903A0 (en) Apilimod for use in the treatment of colorectal cancer
GB201420533D0 (en) Use of Nanomaterials in treating cancer
ZA201707024B (en) Cancer treatment composition
GB201408297D0 (en) Treatment of cancer
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
GB201417456D0 (en) Treatment of cancer
ZA201403006B (en) Composition for use in treatment of cancer
GB201410695D0 (en) Uses of oligouronates in cancer treatment
ZA201404780B (en) Composition for use in treatment of diabetes
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201418272D0 (en) Composition & methods of treatment